Want to see IART full AI Analyst Report?
IART Stock Chart & Stats
$16.88
-$0.26(-1.31%)
At close: 4:00 PM EDT
$16.88
-$0.26(-1.31%)
Day’s Range― - ―
52-Week Range$8.70 - $20.49
Previous Close$19.92
Volume1.02M
Average Volume (3M)1.06M
Market Cap
$1.05B
Enterprise Value$3.18B
Total Cash (Recent Filing)$311.93M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Mar 03, 2027EPS Estimate
0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding77,772,510
10 Day Avg. Volume1,230,855
30 Day Avg. Volume1,064,905
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.91
Price to Sales (P/S)0.58
P/FCF Ratio-21.06
Enterprise Value/Market Cap3.04
Enterprise Value/Revenue1.92
Enterprise Value/Gross Profit3.66
Enterprise Value/Ebitda13.60
Forecast
1Y Price Target
$16.00Price Target Upside-5.21% Downside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)2.41
Revenue Forecast (FY)$1.66B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables DemandIntegra’s meaningful consumables mix ties revenue to procedures and patient treatment rather than only infrequent capital-equipment purchases. Repeat demand across neurosurgery, CSF management, wound care and tissue repair can support customer continuity and make the business model more durable over the next several quarters.
Neurosurgery GrowthNeurosurgery is showing durable momentum across CereLink, Certas Plus, Bactiseal, DuraSeal and cranial perforators despite the Cincinnati headwind. Broad product-level growth and management’s expectation for longer-term low- to mid-single-digit growth support Integra’s specialty position.
Improving Cash GenerationRecord quarterly operating cash flow and strongly positive free cash flow improve Integra’s ability to fund operations, repay debt and invest in product initiatives. Although cash conversion has been uneven historically, the current generation supports balance-sheet repair and provides useful financial capacity.
Bears Say
Elevated LeverageIntegra’s capital structure is materially more leveraged than in earlier periods, reducing flexibility when earnings or operations weaken. Higher debt also increases the importance of sustained cash generation and disciplined capital allocation, while limiting the company’s ability to pursue growth investments.
Unstable ProfitabilityThe sharp movement from prior earnings to a substantial loss and then approximate breakeven shows that reported profitability has not yet become dependable. This weakens confidence in sustainable earnings power and leaves future results more exposed to execution, mix and operating-cost pressures.
Extended Cincinnati DisruptionThe Cincinnati disruption is not confined to one quarter: it is expected to affect the first quarter of 2027 and may permanently cede some demand to smaller competitors. Prolonged production constraints therefore create sustained revenue, margin and customer-retention pressure.
Integra Lifesciences News
IART FAQ
What was Integra Lifesciences Holdings Corp.’s price range in the past 12 months?
Integra Lifesciences Holdings Corp. lowest stock price was $8.70 and its highest was $20.49 in the past 12 months.
What is Integra Lifesciences Holdings Corp.’s market cap?
Integra Lifesciences Holdings Corp.’s market cap is $1.05B.
When is Integra Lifesciences Holdings Corp.’s upcoming earnings report date?
Integra Lifesciences Holdings Corp.’s upcoming earnings report date is Mar 03, 2027 which is in 132 days.
How were Integra Lifesciences Holdings Corp.’s earnings last quarter?
Integra Lifesciences Holdings Corp. released its earnings results on Oct 21, 2026. The company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.557 by $0.033.
Is Integra Lifesciences Holdings Corp. overvalued?
According to Wall Street analysts Integra Lifesciences Holdings Corp.’s price is currently Overvalued.
Does Integra Lifesciences Holdings Corp. pay dividends?
Integra Lifesciences Holdings Corp. does not currently pay dividends.
What is Integra Lifesciences Holdings Corp.’s EPS estimate?
Integra Lifesciences Holdings Corp.’s EPS estimate is 0.71.
How many shares outstanding does Integra Lifesciences Holdings Corp. have?
Integra Lifesciences Holdings Corp. has 77,772,510 shares outstanding.
What happened to Integra Lifesciences Holdings Corp.’s price movement after its last earnings report?
Integra Lifesciences Holdings Corp. reported an EPS of $0.59 in its last earnings report, beating expectations of $0.557. Following the earnings report the stock price went down -16.549%.
Which hedge fund is a major shareholder of Integra Lifesciences Holdings Corp.?
Currently, no hedge funds are holding shares in IART
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Integra Lifesciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$16.00 (-5.21% Downside)
$16.00 (-5.21% Downside)
Blogger Sentiment
Bullish
IART Sentiment 63%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 72.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.04%
12-Months-Change
Fundamentals
Return on Equity
-0.69%
Trailing 12-Months
Asset Growth
-2.85%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Integra Lifesciences Holdings Corp.
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
IART Company Deck
IART Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented meaningful operational and financial progress, including record quarterly operating cash flow, leverage reduction, successful refinancing, improved product availability, strong neurosurgery performance, and several 2027 growth initiatives. However, these positives were balanced by the Cincinnati disruption, reduced revenue and EPS outlooks, Tissue Reconstruction weakness, gross-margin pressure, higher refinancing-related interest expense, and continued competitive and execution challenges. Overall sentiment was balanced, with a constructive long-term outlook but significant near-term headwinds.View all IART earnings summariesIART Stock 12 Month Forecast
Average Price Target
$16.00
▼(-5.21% Downside)
Technical Analysis
Ownership Overview
3.26% Insiders
30.27% Mutual Funds
<0.01% Other Institutional Investors
37.31% Public Companies and
Individual Investors